Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2021 09:00 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma Tolerable...
December 07, 2021 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
November 12, 2021 07:00 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a...
November 10, 2021 16:05 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
November 09, 2021 16:01 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
November 04, 2021 09:00 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
October 26, 2021 16:15 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Announces Change to Management Team and Board of Directors

Julie Eastland Appointed President and Chief Executive Officer Jerry McMahon, Ph.D., Resigns from Harpoon as President and Chief Executive Officer Scott Myers, Current Member of Harpoon’s Board of...
October 05, 2021 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
September 02, 2021 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Participate in Three Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
August 05, 2021 16:05 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Presented updated interim Phase 1/2a clinical trial data for PSMA-targeting TriTAC® HPN424 in prostate cancer at ASCO Annual Meeting Provided clinical trial updates for three additional TriTAC...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right